ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
7.98
+0.05 (0.63%)
At close: May 29, 2026, 4:00 PM EDT
8.04
+0.06 (0.73%)
After-hours: May 29, 2026, 7:59 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, ADMA Biologics stock has a consensus rating of "Buy" and an average price target of $16.75. The average 1-year stock price forecast is 109.90% higher than the current stock price, while the lowest is $12 (+50.38%) and the highest is $20 (+150.63%).
Price Target: $16.75 (+109.90%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $24 → $20 | Buy | Maintains | $24 → $20 | +150.63% | May 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $21 | Buy | Maintains | $21 | +163.16% | May 5, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Downgrades $30 | Hold | Downgrades | $30 | +275.94% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
645.01M
from 510.17M
Increased by 26.43%
Revenue Next Year
740.83M
from 645.01M
Increased by 14.86%
EPS This Year
0.99
from 0.60
Increased by 65.47%
EPS Next Year
1.19
from 0.99
Increased by 19.95%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 672.0M | 820.5M | ||||||
| Avg | 645.0M | 740.8M | ||||||
| Low | 609.7M | 609.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.7% | 27.2% | ||||||
| Avg | 26.4% | 14.9% | ||||||
| Low | 19.5% | -5.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 1.09 | 1.45 | |||||
| Avg | 0.99 | 1.19 | |||||
| Low | 0.85 | 1.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 82.0% | 46.0% | |||||
| Avg | 65.5% | 19.9% | |||||
| Low | 42.1% | 0.7% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.